ArticleWorld journal of clinical oncology2022

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.

Agustín Falco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.